ETNB
- 89bio, Inc.
()
Overview
Company Summary
89bio, Inc. is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of liver and cardio-metabolic diseases. They aim to address unmet medical needs and improve patient outcomes by developing novel drugs that target specific biological pathways related to these conditions.
The company's research and development efforts are primarily focused on developing therapies for Non-Alcoholic Steatohepatitis (NASH) and Primary Hyperoxaluria (PH). NASH is a chronic liver disease characterized by the accumulation of fat in the liver, which can lead to inflammation, fibrosis, and cirrhosis if left untreated. PH is a rare genetic disorder in which excess oxalate, a byproduct of normal metabolism, accumulates in the kidneys and other organs, leading to kidney stones, progressive kidney damage, and other complications.
To tackle these diseases, 89bio leverages its proprietary platform, the BIO89-100 and BIO89-1000 series. These drug candidates are specifically designed to target key molecular pathways involved in NASH and PH pathogenesis, aiming to halt or reverse the progression of these diseases.
89bio's approach involves rigorous clinical trials and collaborations with leading academic institutions and medical centers, bringing together scientific expertise and innovative technologies to develop potential breakthrough therapies. Their goal is to improve the standard of care for patients suffering from liver and cardio-metabolic diseases, ultimately improving their quality of life.
In addition to their focus on drug discovery and development, 89bio also emphasizes patient advocacy and education, engaging with healthcare professionals, patient advocacy groups, and regulatory authorities to raise awareness about the diseases they are targeting and the potential impact of their therapies.
Overall, 89bio, Inc. is dedicated to advancing the field of biopharmaceuticals and making a positive difference in the lives of patients dealing with liver and cardio-metabolic diseases through the development of innovative therapies.